Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.

Some patients with atrial fibrillation (AF) cannot be treated with vitamin K antagonists (VKAs) and will therefore not receive effective thromboprophylaxis. The primary objective of the present Phase II trial (NCT00623779) was to assess the feasibility of conducting a study with a novel oral anticoagulant, the direct thrombin inhibitor AZD0837, in patients with AF unable or unwilling to take warfarin, by evaluation of dropout rates and compliance.
Patients were randomised to receive AZD0837 extended-release tablets 150 mg (n=43) or 300 mg (n = 42) once daily, or standard therapy (no treatment, aspirin 75-325 mg or clopidogrel 75 mg once daily; n = 46) for a median treatment duration of 6 weeks.
Reasons for patients not being treated with warfarin were: refusal or permanent cessation decided by the patient (64.8%), inability to keep international normalised ratio 2-3 over a 3-month period (23.2%), physician assessment that VKA was inappropriate (20.4%) and warfarin allergy (2.8%). Compliance with treatment (mean ± SD) was 97.0 ± 16.5% for AZD0837 150 mg and 99.8 ± 1.4% for 300 mg. Compliance with study visits was high (mean 93-98%). The numbers of dropouts were four, six and three, whilst minor or clinically significant minor bleeds were reported in zero, five and two patients in the AZD0837 150 mg, 300 mg and standard-therapy groups, respectively. No major bleeds were reported. Both doses of AZD0837 reduced levels of fibrin D-dimer and prolonged activated partial thromboplastin time, ecarin clotting time and thrombin clotting time.
AZD0837 had a good safety profile during this study, including a low incidence of bleeding events, with effective anticoagulation on pharmacodynamic parameters. A larger study in AF patients unable or unwilling to take warfarin is feasible, as judged by compliance and dropout rates.
AuthorsGregory Y H Lip, Lars H Rasmussen, S Bertil Olsson, Sofia Zetterstrand, Christina Stahre, Anders Bylock, Maria Aunes-Jansson, Ulf Eriksson, Karin Wåhlander,
JournalThrombosis research (Thromb Res) Vol. 127 Issue 2 Pg. 91-9 (Feb 2011) ISSN: 1879-2472 [Electronic] United States
PMID21172721 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
CopyrightCopyright © 2010 Elsevier Ltd. All rights reserved.
Chemical References
  • AZD 0837
  • Amidines
  • Anticoagulants
  • Azetidines
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D
  • Aged
  • Aged, 80 and over
  • Amidines (administration & dosage, adverse effects, pharmacokinetics)
  • Anticoagulants (administration & dosage, adverse effects, pharmacokinetics)
  • Atrial Fibrillation (blood, complications, drug therapy)
  • Azetidines (administration & dosage, adverse effects, pharmacokinetics)
  • Embolism (blood, etiology, prevention & control)
  • Female
  • Fibrin Fibrinogen Degradation Products (metabolism)
  • Humans
  • Male
  • Medication Adherence
  • Middle Aged
  • Stroke (blood, etiology, prevention & control)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: